- First Patient in Phase 2 Clinical Trial of ATH434 in New ZealandTrial starts in Europe and Australia
- Approval of the FDA’s review application for a new drug to conduct the Phase 2 clinical trial The United States
- Data from the bioMUSE study provide a quantitative measure of MSA progression
- cash balance September 30, 2022 from A$31.9 million
Melbourne, Australia and SAN FRANCISCO , October 28, 2022 /PRNewswire/ — Alterity Therapeutics Limited (ATHATHE (“Alterity” or “the Company”), a biotechnology company dedicated to the development of disease-modifying treatments for neurodegenerative diseases, posts its quarterly cash flow report in Appendix 4C and updates the Company’s activities for the quarter ended December 30ththSep 2022 (Q1FY23).
The company’s cash position September 30, 2022 was $31.9M with operating cash outflows of $4.8Man increase from prior quarters due to the initiation of Alterity’s Phase 2 clinical trial of lead drug candidate ATH434 for the treatment of multiple system atrophy (MSA), a rare Parkinson’s disease with no approved therapy.
Managing Director David StammlerMD, said, “We are excited about the tremendous progress we have made in advancing our Phase 2 clinical trial over the past few months. We have reached an important milestone by dosing our first patient and the study is now ongoing in several countries. MSA is a devastating disease with no current cure, and our team is committed to supporting our research partners around the world in recruiting, evaluating and enrolling patients to pursue our goal of validating our treatment.”
In accordance with ASX Listing Rule 4.7C, payments to related parties and their employees listed in Item 6.1 of Schedule 4C include directors’ fees, consulting fees, remuneration and pensions at normal commercial rates.
operational activities
Alterity achieved significant milestones in the first quarter of 2023.
The first patient was dosed New Zealand in the Company’s Phase 2 clinical trial…
